Condition: Sinusoidal Obstruction Syndrome · Veno-occlusive Disease · Sponsor: New York Medical College
This research study is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with sinusoidal obstructive syndrome (SOS)/veno-occlusive disease (VOD) after hematopoietic cell transplantation (HCT) associated with either kidney and/or lung impairment that has not obtained a complete response (CR) or progressed in severity with standard doses of defibrotide.
This description comes directly from the study's public registry record.
Mitchell Cairo, MD · 914-594-2150 · mitchell_cairo@nymc.edu
Lauren Harrison, MSN · 617-285-7844 · lauren_harrison@nymc.edu
Always discuss trial participation with your own doctor first.
| New York Medical College | Vallhala, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05987124